Market research
AXNX Axonex AI Group Limited
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 72
- Dividend yield
- Not available
- Beta
- 0.83
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 72
- Dividend yield
- Not available
- Beta
- 0.83
About
About Axonex AI Group Limited
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.
Research context
Axonex AI Group Limited appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AXNX discussion.
5 years, 6 months ago
Axonics Modulation Technologies, Inc is currently in a long term uptrend where the price is trading 18.8% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.4.
Axonics Modulation Technologies, Inc's total revenue rose by 249.7% to $35M since the same quarter in the previous year.
Its net income has increased by 50.1% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.9% to $-29M since the same quarter in the previous year.
Based on the above factors, Axonics Modulation Technologies, Inc gets an overall score of 4/5.